PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant Hepatitis B vaccine that enhances the Th1 response
PyNTTTTGT oligodeoxinucleotides (ODNs) cause activation, proliferation and immunoglobulin secretion on B cells, and the expression of co-stimulatory molecules on plasmacytoid dendritic cells of primates. It has now been discovered that these ODNs are also active on rat cells. This fact allowed us to...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
Elsevier BV
2005
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 11068caa a22012857a 4500 | ||
|---|---|---|---|
| 001 | PAPER-4116 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203337.0 | ||
| 008 | 190411s2005 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-18044363849 | |
| 024 | 7 | |2 cas |a aluminum potassium sulfate, 10043-67-1; gamma interferon, 82115-62-6 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a VACCD | ||
| 100 | 1 | |a Elias, F. | |
| 245 | 1 | 0 | |a PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant Hepatitis B vaccine that enhances the Th1 response |
| 260 | |b Elsevier BV |c 2005 | ||
| 270 | 1 | 0 | |m Zorzopulos, J.; Inst. de Invest. Biomédicas, Fund. Pablo Cassará, Saladillo 2452, Buenos Aires (1440), Argentina; email: zorzopul@hotmail.com |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Hepatitis B vaccination - United States, 1982-2002 (2002) MMWR Morb Mortal Wkly Rep, 51, pp. 549-563 | ||
| 504 | |a Incidence of acute hepatitis B - United States, 1990-2002 (2004) MMWR Morb Mortal Wkly Rep, 52 (51-52), pp. 1252-1254. , 2 Jan | ||
| 504 | |a Kubba, A.K., Taylor, P., Graneek, B., Strobel, S., Non-responders to hepatitis B vaccination: A review (2003) Commun Dis Public Health, 6 (2), pp. 106-112 | ||
| 504 | |a Lewis, D.J., Eiden, J.E., Goilav, C., Langenberg, A.G., Suggett, F., Griffin, G.E., Rapid and frequent induction of protective immunity exceeding UK, recommendations for healthcare settings by MF59-adjuvated hepatitis B vaccine (2003) Commun Dis Public Health, 6 (4), pp. 320-324 | ||
| 504 | |a Evans, T.G., Hasan, M., Galibert, L., Caron, D., The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults (2002) Vaccine, 21 (3-4), pp. 322-329 | ||
| 504 | |a Jacques, P., Moens, G., Desombere, I., Dewijngaert, J., Leroux-Roels, G., Wettendorff, M., The immunogenicity and reactogenicity profile of a candidate hepatitis B, vaccine in an adult vaccine non-responder population (2002) Vaccine, 20 (31-32), pp. 3644-3649 | ||
| 504 | |a Davis, H.L., Weeratna, R., Waldschmidt, T.J., Tygrett, L., Schorr, J., Krieg, A.M., Weeranta, R., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen (1998) J Immunol, 160, pp. 870-876 | ||
| 504 | |a Halperin, S.A., Van Nest, G., Smith, B., Abtahi, S., Whiley, H., Eiden, J.J., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant (2003) Vaccine, 21, pp. 2461-2467 | ||
| 504 | |a Krieg, A.M., CpG motifs in bacterial DNA and their immune effects (2002) Annu Rev Immunol, 20, pp. 709-760 | ||
| 504 | |a Elías, F., Fló, J., Lopez, R.A., Zorzopulos, J., Montaner, A., Rodriguez, J.M., Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs (2003) J Immunol, 171, pp. 3697-3704 | ||
| 504 | |a Klinman, D.M., Immunotherapeutic uses of CpG oligonucleotides (2004) Nature Rev Immunol, 4, pp. 249-258 | ||
| 504 | |a Lipford, G.B., Bauer, M., Blank, C., Reiter, R., Wagner, H., Heeg, K., CpG-containing synthetic oligodeoxynucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants (1997) Eur J Immunol, 27, p. 2340 | ||
| 504 | |a Chu, R.S., Targoni, O.S., Krieg, A.M., Lehman, P.V., Harding, C.V., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity (1997) J Exp Med, 186, p. 1623 | ||
| 504 | |a Moldovenu, G.J., Love-Homan, L., Huang, W.Q., Krieg, A.M., CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus (1998) Vaccine, 16, p. 1216 | ||
| 504 | |a Weeratna, R., McCluskie, M.J., Yu, X., Davis, H.L., CpG DNA induces stronger immune responses with less toxicity than other adjuvants (2000) Vaccine, 18, p. 1755 | ||
| 504 | |a Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A.M., Hecker, R., Babiuk, L.A., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved (2001) Antisense Nucleic Acid Drug Dev, 11 (5), pp. 333-340 | ||
| 504 | |a Saoudi, A., Kuhn, J., Huygen, K., De Kozak, Y., Velu, T., Goldman, M., TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease (1993) Eur J Immunol, 23, pp. 3096-3103 | ||
| 504 | |a Gracie, J.A., Bradley, J.A., Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass (1996) Eur J Immunol, 26, pp. 1217-1221 | ||
| 504 | |a Bomford, R., Will adjuvants be needed for vaccines of the future? (1998) Dev Biol Stand, 92, pp. 13-17 | ||
| 504 | |a Gupta, R.K., Aluminum compounds as vaccine adjuvants (1998) Adv Drug Deliv Rev, 32, pp. 155-172 | ||
| 504 | |a Chisari, F.V., Hepatitis B virus immunopathogenesis (1995) Annu Rev Immunol, 13, pp. 29-60 | ||
| 504 | |a Bertoletti, A., D'Elios, M.M., Boni, C., De Carli, M., Zignego, A.L., Durazzo, M., Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections (1997) Gastroenterology, 112 (1), pp. 193-199 | ||
| 504 | |a Guidotti, L.G., Ishikawa, T., Hobbs, M.V., Matzke, B., Schreiber, R., Chisari, F.V., Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes (1996) Immunity, 4 (1), pp. 25-36 | ||
| 504 | |a Jung, M.C., Hartmann, B., Gerlach, J.T., Diepolder, H., Gruber, R., Schraut, W., Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection (1999) Virology, 261 (2), pp. 165-172 | ||
| 504 | |a Penna, A., Del Prete, G., Cavalli, A., Bertoletti, A., D'Elios, M.M., Sorrentino, R., Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B (1997) Hepatology, 25 (4), pp. 1022-1027 | ||
| 504 | |a McGeady, S.J., Immunocompetence and allergy (2004) Pediatrics, 113 (4 SUPPL.), pp. 1107-1113 | ||
| 504 | |a Chung, K.F., Individual cytokines contributing to asthma pathophysiology: Valid targets for asthma therapy? (2004) Curr Opin Invest Drugs, 4 (11), pp. 1320-1326 | ||
| 504 | |a Ronnblom, L., Eloranta, M.L., Alm, G.V., Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity (2003) Autoimmunity, 36 (8), pp. 463-472 | ||
| 504 | |a Conrad, B., Potential mechanisms of interferon-alpha induced autoimmunity (2003) Autoimmunity, 36 (8), pp. 519-523 | ||
| 520 | 3 | |a PyNTTTTGT oligodeoxinucleotides (ODNs) cause activation, proliferation and immunoglobulin secretion on B cells, and the expression of co-stimulatory molecules on plasmacytoid dendritic cells of primates. It has now been discovered that these ODNs are also active on rat cells. This fact allowed us to investigate the adjuvant properties of PyNTTTTGT ODNs in a human Hepatitis B vaccine using this animal model. A very significant increment, as compared with the antigen alone, was observed in the antibody production induced by vaccination with the recombinant Hepatitis B surface antigen adjuvated with the PyNTTTTGT prototype IMT504 ODN. Analysis of the IgG subclass distribution in the sera of vaccinated animals indicated that, although an increase was observed in the titer of all the IgG subclasses, the increase on the Th1-associated IgG2b subclass was clearly more pronounced. Remarkably, this effect on the IgG2b titer was observed even if alum, a Th2 promoting adjuvant, was present together with IMT504 in the vaccine formulation. The increase in the Th1 response induced by IMT504 was also suggested by in vitro gamma interferon secretion assays. Monkeys of the species Cebus apella immunized with the recombinant Hepatitis B surface antigen plus alum and IMT504 also showed titers of antibodies against the antigen several times superior to the titers observed in control animals immunized with the antigen plus alum without ODN. Since rat and monkey cells are significantly less immunostimulated "in vitro" by PyNTTTTGT ODNs than human cells, the present results reasonably predict a very good performance of these ODNs as adjuvants in human vaccination. © 2005 Elsevier Ltd. All rights reserved. |l eng | |
| 593 | |a Depto. de Quím. Biol., Fac. de Ciencias Exactas Y Naturales, Cuidad Universitaria, Buenos Aires (1428), Argentina | ||
| 593 | |a Immunotech S.A, Florida 1, Buenos Aires (1440), Argentina | ||
| 593 | |a Inst. de Invest. Biomédicas, Fund. Pablo Cassará, Saladillo 2452, Buenos Aires (1440), Argentina | ||
| 593 | |a Ctro. Educacion Medica Invest. C., Galvan 4102, Buenos Aires (1431), Argentina | ||
| 690 | 1 | 0 | |a IMMUNOSTIMULATORY OLIGONUCLEOTIDE |
| 690 | 1 | 0 | |a TH1 ANSWER |
| 690 | 1 | 0 | |a VACCINE ADJUVANT |
| 690 | 1 | 0 | |a ALUMINUM POTASSIUM SULFATE |
| 690 | 1 | 0 | |a GAMMA INTERFERON |
| 690 | 1 | 0 | |a HEPATITIS B ANTIGEN |
| 690 | 1 | 0 | |a IMMUNOGLOBULIN G2B |
| 690 | 1 | 0 | |a IMMUNOLOGICAL ADJUVANT |
| 690 | 1 | 0 | |a IMT 504 |
| 690 | 1 | 0 | |a OLIGONUCLEOTIDE |
| 690 | 1 | 0 | |a RECOMBINANT HEPATITIS B VACCINE |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a ANIMAL CELL |
| 690 | 1 | 0 | |a ANIMAL EXPERIMENT |
| 690 | 1 | 0 | |a ANIMAL TISSUE |
| 690 | 1 | 0 | |a ANTIBODY PRODUCTION |
| 690 | 1 | 0 | |a ANTIBODY TITER |
| 690 | 1 | 0 | |a ANTIGEN ANTIBODY REACTION |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a B LYMPHOCYTE |
| 690 | 1 | 0 | |a BIOASSAY |
| 690 | 1 | 0 | |a CELL SECRETION |
| 690 | 1 | 0 | |a CELLULAR IMMUNITY |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a CYTOKINE RELEASE |
| 690 | 1 | 0 | |a DRUG POTENCY |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a HEPATITIS B VIRUS |
| 690 | 1 | 0 | |a IMMUNE RESPONSE |
| 690 | 1 | 0 | |a IMMUNOGLOBULIN PRODUCTION |
| 690 | 1 | 0 | |a IMMUNOSTIMULATION |
| 690 | 1 | 0 | |a IN VITRO STUDY |
| 690 | 1 | 0 | |a MONKEY |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a PHYSICAL CHEMISTRY |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a RAT |
| 690 | 1 | 0 | |a TH1 CELL |
| 690 | 1 | 0 | |a TH2 CELL |
| 690 | 1 | 0 | |a VACCINATION |
| 690 | 1 | 0 | |a VACCINE PRODUCTION |
| 653 | 0 | 0 | |a imt 504, Immunotech, Argentina |
| 700 | 1 | |a Flo, J. | |
| 700 | 1 | |a Rodriguez, J.M. | |
| 700 | 1 | |a De Nichilo, A. | |
| 700 | 1 | |a Lopez, R.A. | |
| 700 | 1 | |a Zorzopulos, J. | |
| 700 | 1 | |a Nagle, C. | |
| 700 | 1 | |a Lahoz, M. | |
| 700 | 1 | |a Montaner, A. | |
| 773 | 0 | |d Elsevier BV, 2005 |g v. 23 |h pp. 3597-3603 |k n. 27 |p Vaccine |x 0264410X |w (AR-BaUEN)CENRE-7118 |t Vaccine | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-18044363849&doi=10.1016%2fj.vaccine.2004.12.030&partnerID=40&md5=ebb506f4034b5c4d59b16f267d393928 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.vaccine.2004.12.030 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_0264410X_v23_n27_p3597_Elias |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0264410X_v23_n27_p3597_Elias |y Registro en la Biblioteca Digital |
| 961 | |a paper_0264410X_v23_n27_p3597_Elias |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 65069 | ||